Foghorn Therapeutics (NASDAQ:FHTX) harnesses its pioneering Gene Traffic Control™ platform to discover and develop innovative therapies targeting diseases with a genetic basis, particularly cancer. The company's mission is centered around unlocking the vast potential of the human genome to revolutionize treatment options for patients battling these serious conditions. Through a deep understanding of chromatin biology, Foghorn Therapeutics strives to lead the way in creating a new wave of precision medicine. Their projects range from early discovery to clinical development, emphasizing a commitment to bringing groundbreaking treatments from the lab bench to bedside.